NAS:CODX (USA) Also Trade In: Germany UK

Co-Diagnostics Inc $ 13.99 0.1 (0.72%)

Volume:

934,057

Avg Vol (1m):

1,778,820

Market Cap $:

394.37 Mil

Enterprise Value $:

367.09 Mil

PE Ratio:

15.51

PB Ratio:

7.83

5D 3M YTD 1Y 5Y 10Y All 10Y (-%)

View Full Chart

What is PE Ratio (TTM)?

Current and historical daily P/E ratio for CODX (Co-Diagnostics Inc) from 2017 to Mar 02 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Co-Diagnostics stock (CODX) PE ratio as of Mar 02 2021 is 15.51. More Details

Co-Diagnostics PE Ratio (TTM) Chart

EMBED

Co-Diagnostics PE Ratio (TTM) Historical Data

View and export this data going back to 2017. Start your Free Trial

Total 915

Co-Diagnostics PE Ratio (TTM) Historical Data
Date	PE Ratio (TTM) Data	Date	PE Ratio (TTM) Data
2021-03-02	15.5	2020-12-24	12.0
2021-03-01	15.4	2020-12-23	12.1
2021-02-26	15.3	2020-12-22	12.5
2021-02-25	17.1	2020-12-21	12.7
2021-02-24	18.5	2020-12-18	12.3
2021-02-23	16.7	2020-12-17	12.1
2021-02-22	17.6	2020-12-16	11.9
2021-02-19	18.9	2020-12-15	12.2
2021-02-18	17.7	2020-12-14	11.8
2021-02-17	19.1	2020-12-11	11.3
2021-02-16	20.2	2020-12-10	11.6
2021-02-15	18.9	2020-12-09	11.3
2021-02-12	18.9	2020-12-08	11.5
2021-02-11	18.0	2020-12-07	11.8
2021-02-10	19.9	2020-12-04	12.3
2021-02-09	21.3	2020-12-03	12.0
2021-02-08	18.8	2020-12-02	12.2
2021-02-05	17.2	2020-12-01	12.3
2021-02-04	17.4	2020-11-30	13.0
2021-02-03	16.3	2020-11-27	13.2
2021-02-02	15.4	2020-11-25	13.5
2021-02-01	15.8	2020-11-24	11.7
2021-01-29	14.3	2020-11-23	11.7
2021-01-28	14.0	2020-11-20	12.3
2021-01-27	14.6	2020-11-19	12.1
2021-01-26	13.9	2020-11-18	12.7
2021-01-25	13.4	2020-11-17	13.2
2021-01-22	13.1	2020-11-16	15.1
2021-01-21	13.2	2020-11-13	16.6
2021-01-20	13.2	2020-11-12	16.9
2021-01-19	13.1	2020-11-11	14.8
2021-01-15	11.7	2020-11-10	13.1
2021-01-14	11.3	2020-11-09	12.8
2021-01-13	11.2	2020-11-06	16.0
2021-01-12	11.5	2020-11-05	16.1
2021-01-11	11.6	2020-11-04	15.8
2021-01-08	12.2	2020-11-03	15.6
2021-01-07	12.0	2020-11-02	14.7
2021-01-06	11.7	2020-10-30	14.9
2021-01-05	11.5	2020-10-29	15.3
2021-01-04	11.1	2020-10-28	15.1
2020-12-31	10.3	2020-10-27	15.8
2020-12-30	10.8	2020-10-26	15.6
2020-12-29	10.9	2020-10-23	13.8
2020-12-28	11.2	2020-10-22	13.5

Co-Diagnostics PE Ratio (TTM) Comparison

Company	Market Cap(Mil)	PE Ratio (TTM)

Business Description

Industry Healthcare » Medical Diagnostics & Research » NAICS : 339112 NAICS : 3841

Compare NAS:LNTH NAS:SRDX NAS:AXDX OTCPK:GWHP NAS:PACB NAS:VIVO NAS:PSNL NAS:QTNT NAS:CSTL NAS:FLGT NYSE:TMO NYSE:DHR NAS:ILMN XAMS:PHIA XSWX:LONN NAS:DXCM NYSE:IQV NYSE:A NAS:IDXX SHSE:603259

Traded in other countries C97.Germany 0A50.UK CODX.USA

Address 2401 South Foothill Drive, Salt Lake City, UT, USA, 84109

Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV. The company's diagnostics systems enable very rapid, low-cost, sophisticated molecular testing for organisms and genetic diseases by greatly automating historically complex procedures in both the development and administration of tests.

Product

Business

Information

About

Affiliate Program

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names

Earn affiliate commissions by embedding GuruFocus Charts

GuruFocus Affiliate Program: Earn up to $400 per referral. Detailed

Disclaimers

GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.